Legal & General Group PLC Inhibrx, Inc. Call Options Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $603M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email